Amarin Corp - ADR (AMRN) Company Profile & Statistics

Amarin Corp - ADR
AMRN
(Nasdaq - US)
Closed
0.55
+0.02 (+4.50%)
in:usd•As of: Nov 22, 2024 15:59 UTC -5
Pre Market:0+0.00 (0.00%)
Open
0.54
High
0.56
Low
0.54

About Amarin Corp - ADR

CEO

Patrick Holt

Headquarters

iconic offices, the greenway, block c ardilaun court,, 112 - 114 street

dublin, l2 dublin 2, ireland

Auditor

Ernst & Young LLP

Employees

275

Share Holders

350

Website

www.amarincorp.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels.

Amarin Corp - ADR Statistics

Valuation Measures

Market Capitalization ²	225.25M
Enterprise Value	67.78M
Enterprise Value/EBITDA (ttm)	-1.65
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	0.42
Price to Sales (ttm)	0.93
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	54.67%
Operating Margin (ttm)	-16.33%
Profit Margin (ttm)	-20.63%
Return on Equity (ttm)	-7.22%
Return on Invested Capital (ttm)	-7.32%
Return on Assets (ttm)	-4.96%

Income Statement

Revenue (ttm)	241.02M
Revenue Per Share (ttm)	0.59
Gross Profit (ttm)	136.07M
EBITDA (ttm)³	-41.10M
Net Income Avi to Common (ttm)	-39.35M
Diluted EPS (ttm)	-0.09

Share Statistics

Beta (5Y Monthly)	1.92
52-Week Change	-30.56%
S&P500 52-Week Change	31.18%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	411.34M
Dividend Yield	0.00%
Float ⁴	402.62M
% Held by Insiders	1.96%
% Held by Institutions	22.25%

Balance Sheet

Total Cash (mrq)	306.26M
Total Cash Per Share (mrq)	0.74
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	3.23%
Quick Ratio (mrq)	2.11%
Book Value Per Share (mrq)	1.29

Cash Flow

Operating Cash Flow Per Share (ytd)	-0.04
Free Cash Flow (ytd)	-17.71M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Amarin Corp - ADR

Trade With A Regulated Broker